Hemodynamics, fluids & transfusion
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial
Primary resultResult — go to the resultMean risk difference 0.7% 97.5% CI -∞ to 4.3%Authors' conclusion
Among patients having supratentorial meningioma resection, a single intraoperative dose of TXA did not significantly reduce bleeding and was non-inferior with respect to postoperative seizures after surgery.
Study context
- Population
- Patients undergoing supratentorial meningioma resection, Beijing Tiantan Hospital, October 2020 to August 2022all completed follow-up
- Participants
- 600 patients
- Comparison
- Single dose tranexamic acid (TXA) 20 mg/kg after induction vs normal saline
- TXAn = 300
- Normal salinen = 300reference
- Primary endpoint
- Postoperative seizures
- Follow-up
- Within 7 days after surgery
Methodological detailsdouble-blind, placebo-controlled, non-inferiority, parallel-group, single-centre
- Double-blind
- Placebo-controlled
- Non-inferiority
- Parallel-group
- Single-centre
Primary result
As reported in the abstract
Mean risk difference
0.7%
97.5% CI -∞ to 4.3%
P = 0.001 for non-inferiority
Events by treatment group
TXA vs Normal saline
mean risk difference 0.7% (97.5% CI -∞ to 4.3%); P for non-inferiority = 0.001
Secondary outcomes
Secondary outcomes (non-epileptic complications within 7 days, Hb change, estimated intraoperative blood loss)
- No significant differences in any secondary outcome
Oozing, calculated blood loss, recurrent seizures, timing of seizures (post hoc)
- Similar amounts
- Post hoc analysis
Original publication
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. J Clin Anesth. Published 17 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →